Optic Nerve Disorders Treatment Market By Treatment Type, By Indication, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

List of Tables

The global optic nerve disorder treatment market accounted for $3,372.46 million in 2021, and is expected to reach $5,247.82 million by 2031, registering a CAGR of 4.5% from 2022 to 2031.

The optic nerve of the eye is the second cranial nerve, which helps transmit sensory information to the brain for vision. This nerve develops from optic vesicle of the forebrain during fetal development. Damage to the optic nerve or its pathways that lead to the brain may result in the loss of vision.

Different types of optic nerve disorders are prevalent across the globe such as glaucoma, optic nerve atrophy, optic neuritis and others. Most of these disorders are symptomatically treated. The treatments may not improve vision, but they can help to prevent vision loss that may occur further with the disorder.

It is estimated that optic nerve disorder treatment market is expected to experience significant market growth during the forecast period owing to the increasing geriatric population suffering from eye diseases, the launch of innovative technologies, a boost in healthcare expenditure, and higher government support. In addition, increase in investment by players in R&D and presence of robust pipeline candidates and rise in expenditure on the development of healthcare infrastructure, which further facilitate the growth of the market. However, Dearth of skilled professionals expected to impede the market growth. In contrast, surge in healthcare investments in public as well as private sectors are anticipated to provide significant growth opportunities for the optic nerve disorder treatment market.

The optic nerve disorder treatment market is segmented on the basis of treatment type, indication, distribution channel and region. Depending on treatment type, the market is classified into steroidal therapy, immunomodulators therapy and others treatment type. On the basis of indication, the market is categorized into optic neuritis, glaucoma, optic nerve atrophy and others. By distribution channel, the market is classified into hospital pharmacies, drug stores, retail pharmacies and online providers.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The report provides a comprehensive analysis of the key players that operate in the global optic nerve disorder treatment market. The key companies profiled in the report include AbbVie Inc., Alcon Inc, Bausch Health Companies, Inc., Cipla Ltd., Mallinckrodt pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Santen Pharmaceutical Co., Ltd., Teva pharmaceutical industries ltd.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the optic nerve disorders treatment market analysis from 2021 to 2031 to identify the prevailing optic nerve disorders treatment market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the optic nerve disorders treatment market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global optic nerve disorders treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Treatment Type

Steroidal Therapy
Immunomodulators therapy
Others

By Indication

Glaucoma
Optic Neuritis
Others

By Distribution Channel

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

By Region

North America
- U.S.
- Canda
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players

Santen Pharmaceutical Co., Ltd.
AbbVie Inc.
Novartis AG
Bausch Health Companies, Inc.
Merck & Co., Inc.
.Aerie Pharmaceuticals, Inc.
Cipla Ltd
mallinckrodt pharmaceuticals
Pfizer, Inc.
Teva Pharmaceutical Industries Ltd.

Product Code: A14042

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. High bargaining power of suppliers
- 3.3.2. Moderate bargaining power of buyers
- 3.3.3. High threat of substitutes
- 3.3.4. High threat of new entrants
- 3.3.5. Moderate intensity of rivalry
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Increase in prevalence of optic nerve disorder
  - 3.4.1.2. Growth in geriatric population
  - 3.4.1.3. Increase in technological advancement
- 3.4.2. Restraints
  - 3.4.2.1. Dearth of skilled professionals
- 3.4.3. Opportunities
  - 3.4.3.1. Growth potential of emerging economies
3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: OPTIC NERVE DISORDERS TREATMENT MARKET, BY TREATMENT TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Steroidal Therapy
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Immunomodulators therapy
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Others
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: OPTIC NERVE DISORDERS TREATMENT MARKET, BY INDICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Glaucoma
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Optic Neuritis
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Others
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: OPTIC NERVE DISORDERS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Hospital Pharmacies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Drug Stores and Retail Pharmacies
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Online Providers
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: OPTIC NERVE DISORDERS TREATMENT MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Treatment Type
- 7.2.3. Market size and forecast, by Indication
- 7.2.4. Market size and forecast, by Distribution Channel
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Treatment Type
  - 7.2.5.1.3. Market size and forecast, by Indication
  - 7.2.5.1.4. Market size and forecast, by Distribution Channel
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Treatment Type
  - 7.2.5.2.3. Market size and forecast, by Indication
  - 7.2.5.2.4. Market size and forecast, by Distribution Channel
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Treatment Type
  - 7.2.5.3.3. Market size and forecast, by Indication
  - 7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Treatment Type
- 7.3.3. Market size and forecast, by Indication
- 7.3.4. Market size and forecast, by Distribution Channel
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Treatment Type
  - 7.3.5.1.3. Market size and forecast, by Indication
  - 7.3.5.1.4. Market size and forecast, by Distribution Channel
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Treatment Type
  - 7.3.5.2.3. Market size and forecast, by Indication
  - 7.3.5.2.4. Market size and forecast, by Distribution Channel
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Treatment Type
  - 7.3.5.3.3. Market size and forecast, by Indication
  - 7.3.5.3.4. Market size and forecast, by Distribution Channel
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Treatment Type
  - 7.3.5.4.3. Market size and forecast, by Indication
  - 7.3.5.4.4. Market size and forecast, by Distribution Channel
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Treatment Type
  - 7.3.5.5.3. Market size and forecast, by Indication
  - 7.3.5.5.4. Market size and forecast, by Distribution Channel
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Treatment Type
  - 7.3.5.6.3. Market size and forecast, by Indication
  - 7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Treatment Type
- 7.4.3. Market size and forecast, by Indication
- 7.4.4. Market size and forecast, by Distribution Channel
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Treatment Type
  - 7.4.5.1.3. Market size and forecast, by Indication
  - 7.4.5.1.4. Market size and forecast, by Distribution Channel
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Treatment Type
  - 7.4.5.2.3. Market size and forecast, by Indication
  - 7.4.5.2.4. Market size and forecast, by Distribution Channel
  - 7.4.5.3. India
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Treatment Type
  - 7.4.5.3.3. Market size and forecast, by Indication
  - 7.4.5.3.4. Market size and forecast, by Distribution Channel
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Treatment Type
  - 7.4.5.4.3. Market size and forecast, by Indication
  - 7.4.5.4.4. Market size and forecast, by Distribution Channel
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Treatment Type
  - 7.4.5.5.3. Market size and forecast, by Indication
  - 7.4.5.5.4. Market size and forecast, by Distribution Channel
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Treatment Type
  - 7.4.5.6.3. Market size and forecast, by Indication
  - 7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Treatment Type
- 7.5.3. Market size and forecast, by Indication
- 7.5.4. Market size and forecast, by Distribution Channel
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Treatment Type
  - 7.5.5.1.3. Market size and forecast, by Indication
  - 7.5.5.1.4. Market size and forecast, by Distribution Channel
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Treatment Type
  - 7.5.5.2.3. Market size and forecast, by Indication
  - 7.5.5.2.4. Market size and forecast, by Distribution Channel
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Treatment Type
  - 7.5.5.3.3. Market size and forecast, by Indication
  - 7.5.5.3.4. Market size and forecast, by Distribution Channel
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Treatment Type
  - 7.5.5.4.3. Market size and forecast, by Indication
  - 7.5.5.4.4. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

9.1. Santen Pharmaceutical Co., Ltd.
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
- 9.1.6. Business performance
- 9.1.7. Key strategic moves and developments
9.2. AbbVie Inc.
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
- 9.2.6. Business performance
- 9.2.7. Key strategic moves and developments
9.3. Novartis AG
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
- 9.3.7. Key strategic moves and developments
9.4. Pfizer, Inc.
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
- 9.4.6. Business performance
9.5. Bausch Health Companies, Inc.
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Business performance
9.6. Teva Pharmaceutical Industries Ltd.
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
- 9.6.6. Business performance
- 9.6.7. Key strategic moves and developments
9.7. mallinckrodt pharmaceuticals
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
- 9.7.6. Business performance
9.8. Merck & Co., Inc.
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
- 9.8.6. Business performance
9.9. .Aerie Pharmaceuticals, Inc.
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Cipla Ltd
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio